BACKGROUND: Cancer therapy-related cardiac dysfunction frequently occurs in patients receiving anthracycline. Ivabradine reduces heart rate without affecting contractility and showed anti-inflammatory, antioxidant, and antiapoptotic effects in experimental cardiotoxicity models. This study aims to evaluate the effect of ivabradine on cancer therapy-related cardiac dysfunction in patients with lymphoma or sarcoma treated with anthracycline. METHODS: In a randomized, triple-blind trial, patients starting anthracycline therapy received either ivabradine 5 mg twice daily or placebo until 30 days after completing treatment. The primary outcome was the incidence of cardiotoxicity measured as a ≥10% relative reduction in global longitudinal strain at 12 months from baseline. Secondary outcomes included 12-month clinical outcomes, a ≥10% decrease in the left ventricular ejection fraction to <
55%, diastolic dysfunction, and troponin T and N-terminal pro-B-type natriuretic peptide levels. RESULTS: This study enrolled 107 patients (51 in the ivabradine group and 56 in the placebo group). The median dose of anthracycline was 300 mg/m CONCLUSIONS: A fixed 10 mg/day dose of ivabradine does not protect patients with cancer against anthracycline cardiotoxicity. REGISTRATION: URL: https://clinicaltrials.gov/
Unique Identifier: NCT03650205.